Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04692103 · ClinicalTrials.gov registry record · Phase 2
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
A Phase 2 study of Stage IV Breast Cancer AJCC v6 and v7 and Estrogen Receptor Positive, sponsored by University of Washington.
- Active
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT04692103: Active Phase 2 study of Stage IV Breast Cancer AJCC v6 and v7 and Estrogen Receptor Positive, sponsored by University of Washington.
NCT04692103 is a Phase 2 study of Stage IV Breast Cancer AJCC v6 and v7 and Estrogen Receptor Positive that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 2 participants, below the 137-participant average among 14 other Stage IV Breast Cancer AJCC v6 and v7 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04692103, a Phase 2 study of Stage IV Breast Cancer AJCC v6 and v7 and Estrogen Receptor Positive, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies use of F-18 16 alpha-fluoroestradiol (\[F-18\] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.
Primary Outcome
FES uptake will be quantified using lean body mass adjusted SUV (SUL). Percentage change in FES average SULmax between baseline and a second FES scan will be calculated for up to 3 lesions per patient.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- DRUG F-18 16 Alpha-Fluoroestradiol
- DRUG Fludeoxyglucose F-18
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-07-10 |
| Est. Completion | 2041-04-30 |
| Phase | Phase 2 |
What the registry record for NCT04692103 still lists
NCT04692103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 137-participant average among 14 other Stage IV Breast Cancer AJCC v6 and v7 trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Stage IV Breast Cancer AJCC v6 and v7 appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT04692103 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT04692103 about?
NCT04692103 is a clinical study titled "Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy". This clinical trial studies use of F-18 16 alpha-fluoroestradiol (\[F-18\] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has com...
What is the current status of trial NCT04692103?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-07-10. Estimated completion is 2041-04-30.
What conditions does trial NCT04692103 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer AJCC v6 and v7, Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma.
What interventions are being tested in trial NCT04692103?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), F-18 16 Alpha-Fluoroestradiol (DRUG), Fludeoxyglucose F-18 (DRUG).
Who is sponsoring clinical trial NCT04692103?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04692103 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer AJCC v6 and v7
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04692103's enrollment target sits among peer trials
2 14th of 14 the lowest of 14 other Stage IV Breast Cancer AJCC v6 and v7 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Breast Cancer AJCC v6 and v7 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
COMPLETED · Phase 2
-
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI